Skip to main content
SpringerLink
Log in

Heparin-Induced Thrombocytopenia and its Treatment

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998;79:1-7.

    Google Scholar 

  2. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699.

    Google Scholar 

  3. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988;72:925-930.

    Google Scholar 

  4. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989;73:235-240.

    Google Scholar 

  5. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992;68:95-96.

    Google Scholar 

  6. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251.

    Google Scholar 

  7. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists. Platelets 1999;10:319-326.

    Google Scholar 

  8. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.

    Google Scholar 

  9. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene complicating heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812.

    Google Scholar 

  10. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88.

    Google Scholar 

  11. Warkentin TE, Kelton JG. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT [abstract]. Blood 1998;92(Suppl. 1):182a.

    Google Scholar 

  12. Warkentin TE. Clinical presentation of heparininduced thrombocytopenia. Semin Hematol 1998;35(Suppl. 5):9-16.

    Google Scholar 

  13. Warkentin TE, Kelton JG. A 14-year study of heparininduced thrombocytopenia. Am J Med 1996;101:502-507.

    Google Scholar 

  14. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12-16.

    Google Scholar 

  15. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996;92:494-497.

    Google Scholar 

  16. Warkentin TE, Hirte HW, Anderson DR, Wilson WEC, O'Connell GJ, Lo RC. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994;97:489-91

    Google Scholar 

  17. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparininduced platelet aggregation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-385.

    Google Scholar 

  18. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2000, 211-244.

    Google Scholar 

  19. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemost 1992;67:545-549.

    Google Scholar 

  20. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416.

    Google Scholar 

  21. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35(Suppl. 5):17-25.

    Google Scholar 

  22. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.

    Google Scholar 

  23. Greinacher A, Warkentin TE. Treatment for heparin-induced thrombocytopenia: An overview. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2000, 261-290.

    Google Scholar 

  24. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis, frequency, avoidance and management. Drug Safety 1997;17:325-341.

    Google Scholar 

  25. Demers C, Ginsberg JS, Brill-Edwards P, Panju A, Warkentin TE, Anderson DR, Turner C, Kelton JG. Rapid anticoagulation using ancrod for heparininduced thrombocytopenia. Blood 1991;78:2194-2197.

    Google Scholar 

  26. Pollak VE, Glas-Greenwalt P, Olinger CP, et al. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325.

    Google Scholar 

  27. Gupta AK, Kovacs MJ, Sauder DN. Heparin-induced thrombocytopenia. Ann Pharmacother 1998;32:55-59.

    Google Scholar 

  28. Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992;22:58-65.

    Google Scholar 

  29. Warkentin TE, Barkin RL. Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy 1999;19:181-195.

    Google Scholar 

  30. Chong BH. Danaparoid for the treatment of heparininduced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, 2000, 291-311.

    Google Scholar 

  31. Newman PM, SwansonRL Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-297

    Google Scholar 

  32. Warkentin TE. Danaparoid (Orgaran®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects on in vivo thrombin and crosslinked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG [abstract]. Blood 1996;88(Suppl 1):626a.

    Google Scholar 

  33. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73-80.

    Google Scholar 

  34. Greinacher A, Janssens U, Berg G, Böck M, Kwasny H, Kemkes-Matthes B, Eichler P, Völpel H, Pötzsch B, Luz M. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593.

    Google Scholar 

  35. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-25.

    Google Scholar 

  36. Greinacher A, Eichler P, Kwasny H, Luz M. Lepirudin for parenteral anticoagulation of patients with heparin-induced thrombocytopenia (HIT) and thrombosis: Metaanalysis of two prospective studies and evaluation of the optimal aPTT range [abstract]. Thromb Haemost 1999;82(Suppl.):211.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Theodore E. Warkentin

Authors
  1. Theodore E. Warkentin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warkentin, T.E. Heparin-Induced Thrombocytopenia and its Treatment. J Thromb Thrombolysis 9 (Suppl 1), 29–35 (2000). https://doi.org/10.1023/A:1018708419564

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018708419564

Keywords

Search

Navigation